Related Experiment Video

Updated: Apr 28, 2026

Glycan Node Analysis: A Bottom-up Approach to Glycomics
11:36

Glycan Node Analysis: A Bottom-up Approach to Glycomics

Published on: May 22, 2016

10.1K

Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing

Lan He1, Hongguang Bao, Jing Xue

  • 1Basic Medical Science College, Qiqihar Medical University, Bukui North Street 333, Jianhua District, Qiqihar, 161006, Heilongjiang, China.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|May 31, 2014
PubMed

Insights

Circulating soluble receptor for advanced glycation end products (sRAGE) levels are significantly lower in cancer patients compared to healthy individuals. This suggests sRAGE may play a protective role in cancer development, particularly in those without diabetes or with normal kidney function.

Area of Science:

  • Oncology
  • Biomarkers
  • Molecular carcinogenesis

Background:

  • Receptor for advanced glycation end products (RAGE) is implicated in cancer progression and metastasis.
  • Understanding the role of circulating soluble RAGE (sRAGE) in carcinogenesis is crucial for developing targeted therapies.
  • Previous studies have suggested a link between sRAGE and various cancer types, but a comprehensive analysis is needed.

Purpose of the Study:

  • To conduct a meta-analysis examining the association between circulating soluble RAGE (sRAGE) and all types of cancer.
  • To quantify the difference in sRAGE levels between cancer patients and control groups.
  • To explore potential sources of heterogeneity in the observed association.

Main Methods:

  • Systematic literature search of PubMed and EMBASE databases up to March 1, 2014.
  • Meta-analysis of nine eligible studies including 1,337 cancer patients and 1,839 controls.
  • Data extraction and quality assessment performed in duplicate; effect estimates calculated as weighted mean difference (WMD) with 95% confidence intervals (CI).

Main Results:

  • Overall analysis revealed significantly reduced circulating sRAGE levels in cancer patients compared to controls (WMD = -222.07 pg/ml; 95% CI: -373.77 to -70.37; P = 0.004).
  • Subgroup analyses showed a significant reduction in prospective studies (WMD = -87.62 pg/ml; P = 0.001) and large studies (≥200 subjects; WMD = -231.34 pg/ml; P = 0.038).
  • Meta-regression indicated that smoking status partially explained the heterogeneity in the sRAGE-cancer association (P = 0.046).

Conclusions:

  • Circulating sRAGE levels are significantly lower in individuals with cancer, suggesting a potential protective role in cancer development.
  • The findings are particularly relevant for patients without diabetes mellitus or with normal renal function.
  • Further research is warranted to elucidate the precise mechanisms underlying the association between sRAGE and cancer risk.

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.2K

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.5K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
862
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K